These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12229003)

  • 1. [Is pneumococcal conjugate vaccine needed?].
    Nuorti P
    Duodecim; 2002; 118(1):77-9. PubMed ID: 12229003
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine policy decisions: tension between science, cost-effectiveness and consensus?
    Zimmerman RK; Jackson RE
    Am Fam Physician; 2001 May; 63(10):1919, 1923. PubMed ID: 11388708
    [No Abstract]   [Full Text] [Related]  

  • 3. Pneumococcal vaccine: to vaccinate or to revaccinate--that is the question.
    Uiterwyk SH
    Med Health R I; 2004 Mar; 87(3):68-71. PubMed ID: 15085683
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
    Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for?
    Heininger U
    Eur J Pediatr; 2002 Dec; 161 Suppl 2():S125-6. PubMed ID: 12494257
    [No Abstract]   [Full Text] [Related]  

  • 10. Information from your family doctor. Pneumococcal conjugate vaccine: what a parent needs to know.
    Am Fam Physician; 2001 May; 63(10):2003-4. PubMed ID: 11388716
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine.
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2002 Jan; 28(ACS-2):1-32. PubMed ID: 12728645
    [No Abstract]   [Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
    Ray GT
    Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for other neonatal infections: pneumococcal disease: a major global health problem of young children.
    Richmond P
    Expert Rev Vaccines; 2004 Aug; 3(4):379-82. PubMed ID: 15270639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conjugate vaccines changed the epidemiology of infection].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2006 Aug; 29(8):307-8. PubMed ID: 16927601
    [No Abstract]   [Full Text] [Related]  

  • 20. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.